Eli Lilly Stock in 5 Years:
Bull, Base and Bear Targets

Eli Lilly and Company (LLY) is the rare mega-cap that still grows like a start-up. In the second quarter of 2026 it lifted revenue 48% year over year to $22.974 billion — the kind of number that normally belongs to a company a twentieth of its size — while carrying a market value of roughly $1.08 trillion. That combination is exactly why a five-year forecast is so contested: at about 28.5 times forward earnings, the price already assumes Lilly keeps most of the GLP-1 market it has built. This article lays out a framework — bull, base and bear scenarios for 2031 — and shows the valuation bridge that produces each, so you can weigh the margin of safety when a stock trades at a premium multiple for yourself rather than take a single number on faith.

The Central Tension: 48% Growth at a $1.08 Trillion Valuation

Most of the debate around Lilly can be reduced to one sentence: a company this large is not supposed to grow this fast, and a company growing this fast is not usually priced with this much already assumed. Both halves are true at the same time.

The growth is real and recent. Q2 2026 revenue rose 48% to $22.974 billion, split roughly $14.4 billion in the US (up 33%) and $8.6 billion outside it (up 80%). Reported gross margin was 85.8%, and the company has now beaten non-GAAP earnings estimates for five straight quarters. The price reflects a lot of that. The shares change hands near $1,149 — about 11% below the 52-week high of $1,292.65 and just under the 50-day moving average — which is one reason a five-year piece should read as a framework rather than a victory lap.

That recomputation matters more than it looks. A copied market cap from an earlier, higher price would overstate the company by roughly $90 billion. The habit of recalculating the number from shares and the latest close — rather than trusting a cached figure — is the same discipline the rest of this analysis tries to apply to earnings and growth.

Eli Lilly's Business Today: Where the Money Comes From

Before any 2031 scenario means anything, it helps to see how concentrated the growth engine is. Two tirzepatide brands — Mounjaro for type 2 diabetes and Zepbound for obesity — did the heavy lifting in Q2 2026.

Mounjaro and Zepbound together generated about $14.9 billion, or roughly two-thirds of the $22.974 billion quarter. That concentration is the whole story in miniature: it powers both the bull case (one franchise scaling faster than almost anything in pharma history) and the bear case (that much dependence on a single molecule class, exposed to the same pricing forces at once).

The rest of the portfolio is not trivial. Ebglyss (dermatology) grew 131% off a small base, Jaypirca (oncology) 56%, and newer launches Kisunla (Alzheimer's) and Omvoh (immunology) are beginning to contribute. But over a five-year horizon, the number that decides the outcome is what happens to the incretin franchise.

Mounjaro and Zepbound: The GLP-1 Engine

The engine is running on volume. Demand for GLP-1 medicines has outpaced the industry's ability to make them for most of the past two years, and Lilly has been converting capacity into revenue as fast as it can bring it online. That is why a franchise can grow 90% in a quarter even as the company acknowledges — openly — that the price it captures per prescription is falling. Volume is doing the work; price is a headwind, not a tailwind. Holding those two facts together is the key to reading every scenario later in this article.

Orforglipron (Foundayo): Approved for Obesity, Diabetes Pending

The single most misreported fact about Lilly right now is the status of its oral GLP-1, orforglipron, sold under the brand name Foundayo. Two separate facts must not be merged.

First: Foundayo was FDA-approved for obesity on April 1, 2026, and began shipping through LillyDirect from April 6, 2026, with high-dose average weight loss of about 12.4% reported in its trials. It is approved and launched. Second, and separately: a type 2 diabetes indication for orforglipron was submitted in the US and remained pending as of the Q2 2026 release. Writing that orforglipron is unapproved, or that the diabetes indication is already cleared, gets the story backwards. An oral small-molecule that works without injection or cold-chain logistics is the format that could take GLP-1s from a supply-constrained specialty product to something closer to a mass-market medicine — which is precisely why the competitive timing question (covered later) is so important.

GAAP vs Non-GAAP: Reading Lilly's Earnings Correctly

Lilly is a case study in why earnings basis matters. The stock's trailing P/E of 40.5x is derived from GAAP trailing EPS of $29.80. The company's five reported quarterly earnings figures, and its full-year 2026 guidance, are on a non-GAAP basis. The two do not add up to the same thing — and that is not an error, it is the point.

Add the four most recent non-GAAP quarters — $8.38, $8.55, $7.54 and $7.02 — and you get $31.49. The GAAP trailing EPS is $29.80. The gap between $31.49 and $29.80 is exactly why you can never divide a GAAP-based trailing P/E by a non-GAAP EPS figure and expect it to reconcile. When this article anchors its scenarios, it uses the non-GAAP guidance base ($35.50–$36.50 for FY2026) and keeps it labelled as non-GAAP throughout; it never blends it with the GAAP trailing multiple. One more caveat travels with that guidance: the non-GAAP EPS range includes $3.03 of acquired in-process R&D (IPR&D) charges, so the underlying run-rate is a little higher than the headline suggests.

One footnote on the payout: Lilly does pay a dividend, yielding about 0.75% with a payout ratio near 22% and five-year dividend growth near 15% a year; income is a footnote to this story rather than its central feature.

The Valuation Bridge: How 2031 Targets Are Built

A five-year price is not a guess pulled from a chart. It is the product of three numbers: an earnings base, a growth rate over the period, and the multiple the market is willing to pay at the end. Change any one and the answer moves — often violently. The point of showing the bridge is to make those assumptions visible instead of hiding them inside a single headline figure.

The three scenarios below apply that same arithmetic with different assumptions. They are deliberately spread wide, because five years is a long time in a category where price, competition and sentiment are all in motion.

Forward P/E, Revenue Growth and the Multiple Debate

The live debate is not really about whether Lilly grows — it is about what multiple slower growth deserves. Today the market pays about 28.5x forward earnings for roughly 48% revenue growth. Nobody expects 48% forever. The question is how the multiple travels as growth decelerates. If the three numbers behind a P/E ratio are new to you, the short version is that a multiple is the market's paid-for expectation of future growth; when the expected growth rate falls, the multiple usually falls with it, even if earnings keep rising.

That is the mechanism that separates the base case from the bear case. In the base case, earnings keep compounding at a healthy clip and the multiple drifts from 28.5x toward the mid-20s — a gentle re-rating that still leaves the stock ahead. In the bear case, earnings growth halves and the multiple falls to the mid-teens at the same time. When both the numerator (earnings growth) and the denominator (the multiple) move against you together, the price outcome is far worse than either move alone would suggest.

Bull Case: The Upside Scenario for 2031

The bull case does not require heroics on the drug side — the drugs already work and already sell. It requires that Lilly keeps roughly the share of the GLP-1 market that today's price implies, and that the oral format expands the total market rather than just cannibalizing the injectables.

In illustrative terms, that path looks like non-GAAP EPS compounding around 20% a year from the ~$36 base to roughly $90 by 2031, with the market still willing to pay about 30x for a franchise that has proven it can defend its lead and widen the addressable population through Foundayo and the pipeline. At $90 and 30x, the model prints an illustrative ~$2,700 per share — a little over 18% a year in price from the current level. The scaffolding under that number is a genuine oral advantage in the US, ex-US expansion running at 80% growth, and a pipeline (retatrutide) that could refresh the franchise before tirzepatide's exclusivity is even a five-year question. The bull case is not that nothing goes wrong; it is that volume keeps outrunning price by a wide enough margin, for long enough, that the premium multiple survives.

Base Case: The Most Likely 2031 Path

The base case takes the same engine and lets physics catch up to it. Growth stays strong but decelerates as the law of large numbers bites and as realized prices keep drifting down; the multiple compresses toward the mid-20s as the market re-rates a slower grower.

That is the ~12% EPS-growth, 24x-multiple path in the bridge: about $63 of non-GAAP EPS in 2031 and an illustrative ~$1,510 per share, roughly 5–6% a year in price before the dividend. In this world Lilly still has category-leading margins, a deep pipeline and a genuine oral advantage — but the market gradually re-rates it from hyper-growth toward high-quality large-cap pharma. The share of the GLP-1 market it holds is large but no longer expanding; competition and price negotiation nibble at the edges without breaking the franchise. It is the least dramatic outcome and, arguably for that reason, the most plausible: a very good business slowly being priced like a very good business rather than a miracle.

Bear Case: Why the Patent Cliff Is NOT the Five-Year Risk

Here is the single most important correction in this entire piece, because most competing forecasts get it wrong: the tirzepatide patent cliff is not the five-year bear case. The tirzepatide compound patent runs to January 2036, and formulation and device patents may extend exclusivity toward 2039-2041 (this outer bound is contested and drawn from secondary patent-tracking sources, not settled fact). Every one of those dates sits beyond a 2031 horizon. A five-year bear case built on loss of exclusivity is analytically wrong.

So where does the real bear case come from? Four things that are all live today: realized-price erosion, competition, execution risk, and multiple compression. In the bear path, non-GAAP EPS grows only about 6% a year — because price gives back more of what volume gains — and the market re-rates the stock from a growth multiple to a pharma multiple, from 28.5x down toward 15x. That is roughly $48 of EPS at 15x, an illustrative ~$720 per share, or about a third below the current price. Note what is doing the damage: not a patent expiry, but the ordinary forces of a maturing, competitive, price-pressured market arriving faster than the current multiple assumes.

Pricing Pressure Is Already in the Numbers

The reason the bear case is credible is that its central mechanism is not hypothetical — it is already disclosed. The Q2 2026 release attributes part of the growth on every GLP-1 line to lower realized prices: US Mounjaro, ex-US Mounjaro (following a China NRDL national-formulary listing from Q1 2026), and US Zepbound (after announced cash-pay price reductions). In plain terms, the company is telling investors that it is trading price for volume, and that the reported growth rate flatters what is happening to revenue per unit.

For now, volume is winning by such a margin that it barely shows. The bear case is simply the wearing-down of that margin — a world where each new market entered and each new payer negotiation costs a little more price than the last, until price erosion is large enough to slow earnings growth even as prescriptions keep rising. You do not have to imagine that world; you can watch its first innings in the quarterly disclosures.

How Lilly Compares to Its Pharma Peers

Against its large-cap pharma peers, Lilly is an outlier on both growth and price. The table below keeps every ratio on a single, internally comparable basis so the growth premium is visible rather than distorted.

The takeaway is straightforward. Lilly grows several times faster than every name in the group and carries the highest margins, and it is priced accordingly — a 28.5x forward multiple against 8-21x for the others, and a price/sales ratio (13.6x) that is roughly double the next-highest. That premium is the growth premium. The peer table does not tell you whether it is justified; it tells you exactly how much better Lilly has to keep performing to earn it. For readers wanting a broader map of the category, the two faster-growing specialty names Vertex and Regeneron sit at more moderate forward multiples (around 24x and 14x) with revenue growth in the 9-10% range — useful context, but a different cohort from the big-cap peers above.

The Novo Nordisk Question: Who Wins the Oral GLP-1 Market

The competitive contrast that matters most is not in the table — it is Novo Nordisk, and it belongs in prose because its numbers are reported on a different basis. In Q2 2026, Novo grew adjusted sales just 7% at constant exchange rates (to DKK 78.5 billion) with adjusted operating profit up 11%. Lilly grew 48%. On raw momentum, it is not close.

And yet Novo reached the oral obesity market first, with a Wegovy pill generating about $355 million in its first quarter. That is the crux of the five-year share-retention question. Lilly is the faster-growing company with a deep incretin pipeline; Novo got a mass-market oral format to patients ahead of it. Whether Lilly's superior growth or Novo's first-mover oral position proves more durable is genuinely unsettled — and it is one of the assumptions that separates the bull case (Lilly retains and expands share) from the bear case (a well-armed competitor caps how much of the market Lilly ultimately keeps). This article deliberately does not quote a prescription market-share percentage for either side, because a reliable figure could not be traced to a primary source; the honest version of the comparison is the growth-rate and first-mover contrast, not a false-precision share number.

Key Risks to Every Scenario

Every scenario above rests on assumptions that could break. The main risks are worth stating plainly.

• Realized-price erosion accelerates. The disclosed price-for-volume trade could deepen faster than the base case assumes as more markets list on national formularies and cash-pay competition intensifies.
• Multiple compression. At 28.5x forward earnings, even a flawless operating record can produce a poor return if the market simply decides to pay less for the same growth. The multiple is the single biggest swing factor in the bridge.
• Concentration. Two tirzepatide brands drive roughly two-thirds of revenue; any clinical, regulatory or manufacturing setback in that franchise hits disproportionately.
• Competition. Novo's first-mover oral position, and the broader field of incretin developers, could cap the share Lilly retains.
• Execution. Scaling manufacturing, launching new indications, and integrating pipeline assets all carry ordinary execution risk that a 48%-growth valuation leaves little room to absorb.

Retatrutide and the 2027 Pipeline Catalysts

One reason the bull case does not depend on the patent horizon is the pipeline behind tirzepatide. A retatrutide BLA — a next-generation incretin candidate targeting obesity, sleep apnea and osteoarthritis — is planned for Q1 2027. If it delivers, it offers a way to refresh and defend the franchise well before exclusivity is even a live concern, which is exactly why the five-year story is about share and price rather than patents. Pipeline outcomes are uncertain by nature, so this is a lever, not a promise.

What the Q3 2026 Print (Oct 29) Could Signal

Q3 2026 results are scheduled for October 29, 2026, with consensus non-GAAP EPS of about $9.88 and revenue of roughly $22.4 billion. This article is written to be evergreen and does not hinge on that print, but it is the next place to test the central tension: watch whether volume growth is still comfortably outrunning the disclosed price erosion, and whether guidance moves again. A print that shows accelerating price pressure without matching volume would nudge the weight of evidence toward the bear mechanism; the reverse would support the bull.

Frequently Asked Questions

Is Eli Lilly stock a good investment right now?

That depends on assumptions you have to supply yourself: how much of the GLP-1 market Lilly keeps, how fast realized prices fall, and what multiple the market pays for slower-but-still-large growth in 2031. The stock trades at about 28.5x forward earnings, roughly 11% below its 52-week high — a premium that rewards continued execution and punishes disappointment. This article provides the framework; the judgment is yours, and ideally your financial adviser's.

What will Eli Lilly stock be worth in 5 years?

No one can know. The illustrative model in this article spans roughly $720 (bear) to $2,700 (bull) per share by 2031, with a base case near $1,510 — but those are outputs of chosen assumptions, not forecasts. Past performance does not guarantee future results.

When does Eli Lilly's tirzepatide patent expire?

The tirzepatide compound patent runs to January 2036, and formulation and device patents may extend exclusivity toward 2039-2041 (contested and secondary-sourced). All of that sits beyond a five-year, 2031 horizon, which is why loss of exclusivity is not the five-year bear case.

Is orforglipron (Foundayo) FDA approved?

Yes, for obesity: Foundayo was FDA-approved on April 1, 2026 and launched via LillyDirect from April 6, 2026, with high-dose average weight loss of about 12.4%. A separate type 2 diabetes indication was submitted in the US and remained pending as of the Q2 2026 release.

How is Eli Lilly different from Novo Nordisk?

In Q2 2026 Lilly grew revenue 48% while Novo Nordisk grew adjusted sales 7% at constant exchange rates — but Novo reached the oral obesity market first, with a Wegovy pill generating about $355 million in its first quarter. The five-year question is whether Lilly's faster growth or Novo's first-mover oral position matters more.

When is Eli Lilly's next earnings date?

Q3 2026 results are scheduled for October 29, 2026, with consensus non-GAAP EPS of about $9.88 and revenue of roughly $22.4 billion. This article is written to be evergreen and does not depend on that print.